ADT, BMW and Duchossois Group have achieved exits after people-tracking app developer Life360 became one of the few US-based companies to float in Australia.

Metabolic therapy developer Axcella Health has priced its shares at $20 each in an offering that enabled Nestlé Health Science to exit.

The immunotherapy developer, which counts Eli Lilly, Pfizer, Taiho and Ping An as investors, floated in the middle of its range after raising $160m in venture funding.

Lundbeck-backed pruritus therapy developer Trevi Therapeutics raised $55m when it floated, but had to price its shares significantly below its range.

SoftBank Vision Fund is selling $245m of shares while PayPal is investing $500m in the ride hailing service, in the world's largest IPO since 2014.

Milestone, a cardiovascular nasal spray developer that raised more than $167m in VC funding from investors including Novo, secured $82.5m in when it went public.

Pfizer, Takeda and Alphabet-backed degenerative disease drug developer Cortexyme priced its initial public offering in the middle of its range to raise $75m.

The Tencent-backed cosmetic procedure-booking and social media platform floated at the top of its range in a US offering that came after more than $229m of funding.

Pharmstandard, Lung Biotechnology and Posco celebrated exits as the organ transportation system developer went public in a $91m offering.

General Mills-backed meat substitute developer Beyond Meat priced its shares at the top of an expanded range, but Tyson Foods had already sold its stake.